Simufilam Slowed Cognitive Decline in a Randomized Withdrawal Trial of Mild-to-Moderate Alzheimer’s Disease
- Pharmacology/BS
- · 2023. 7. 6.
Propanc Biopharma, Inc. announced the successful production of synthetic recombinant proenzymes trypsinogen and chymotrypsinogen through the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program. The project was conducted in collaboration with the Universities of Jaén and Granada, Spain. The synthetic development of these proenzymes aims to create a backup clinical co..
The Kleine-Levin Syndrome Foundation today announced updated diagnostic criteria for Kleine-Levin Syndrome (KLS) published in the International Classification of Sleep Disorders Third Edition (ICSD-3), the leading resource for diagnosing sleep disorders distributed by the American Academy of Sleep Medicine (AASM). The updated information about KLS in the ICSD-3 is based in large part on medical ..
Liberate Medical Secures $6.2M in Series B Financing Series B Co-Led by a Large Strategic Investor and Scientific Health Development to Support the Pivotal Clinical Trial of the VentFree® Respiratory Muscle Stimulator CRESTWOOD, Ky.--(BUSINESS WIRE)-- Liberate Medical, an emerging leader in the development of novel non-invasive neurostimulation devices focused on transforming respiratory care, a..
Ayala Pharmaceuticals, Inc. has successfully concluded an End-of-Phase 2 meeting with the FDA regarding AL102, a potential treatment for desmoid tumors. The company confirms agreement with the FDA on key elements of the Phase 3 segment of the ongoing RINGSIDE study, including the dosing regimen. Enrollment in Phase 3 is continuing as planned. Desmoid tumors are rare connective tissue tumors that..
F-star Therapeutics, an invoX company, has announced a strategic collaboration and license agreement with Takeda to discover and develop next-generation multi-specific antibodies. The collaboration will focus on using F-star's proprietary platforms to research and develop immunotherapies for cancer patients. Under the agreement, F-star and Takeda will work together to research and develop novel ..
InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and effi..